DBV Technologies (DBVT) Competitors $14.86 -0.26 (-1.72%) Closing price 04:00 PM EasternExtended Trading$14.91 +0.05 (+0.34%) As of 06:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DBVT vs. IMCR, VCEL, JANX, EWTX, RCUS, HRMY, AUPH, PAHC, SDGR, and HROWShould you be buying DBV Technologies stock or one of its competitors? The main competitors of DBV Technologies include Immunocore (IMCR), Vericel (VCEL), Janux Therapeutics (JANX), Edgewise Therapeutics (EWTX), Arcus Biosciences (RCUS), Harmony Biosciences (HRMY), Aurinia Pharmaceuticals (AUPH), Phibro Animal Health (PAHC), Schrodinger (SDGR), and Harrow (HROW). These companies are all part of the "pharmaceutical products" industry. DBV Technologies vs. Its Competitors Immunocore Vericel Janux Therapeutics Edgewise Therapeutics Arcus Biosciences Harmony Biosciences Aurinia Pharmaceuticals Phibro Animal Health Schrodinger Harrow DBV Technologies (NASDAQ:DBVT) and Immunocore (NASDAQ:IMCR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, valuation, media sentiment, profitability and risk. Which has better earnings & valuation, DBVT or IMCR? Immunocore has higher revenue and earnings than DBV Technologies. Immunocore is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDBV Technologies$4.15M98.11-$113.92M-$4.77-3.12Immunocore$310.20M5.13-$51.09M-$0.40-79.00 Is DBVT or IMCR more profitable? Immunocore has a net margin of -5.70% compared to DBV Technologies' net margin of -3,220.49%. Immunocore's return on equity of -5.40% beat DBV Technologies' return on equity.Company Net Margins Return on Equity Return on Assets DBV Technologies-3,220.49% -287.15% -138.83% Immunocore -5.70%-5.40%-1.93% Which has more volatility & risk, DBVT or IMCR? DBV Technologies has a beta of -0.45, suggesting that its stock price is 145% less volatile than the S&P 500. Comparatively, Immunocore has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500. Does the media favor DBVT or IMCR? In the previous week, Immunocore had 5 more articles in the media than DBV Technologies. MarketBeat recorded 5 mentions for Immunocore and 0 mentions for DBV Technologies. DBV Technologies' average media sentiment score of 1.00 beat Immunocore's score of 0.46 indicating that DBV Technologies is being referred to more favorably in the media. Company Overall Sentiment DBV Technologies Positive Immunocore Neutral Do institutionals and insiders have more ownership in DBVT or IMCR? 71.7% of DBV Technologies shares are held by institutional investors. Comparatively, 84.5% of Immunocore shares are held by institutional investors. 1.4% of DBV Technologies shares are held by insiders. Comparatively, 10.4% of Immunocore shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Do analysts rate DBVT or IMCR? DBV Technologies currently has a consensus price target of $14.75, indicating a potential downside of 0.74%. Immunocore has a consensus price target of $56.89, indicating a potential upside of 80.03%. Given Immunocore's higher possible upside, analysts plainly believe Immunocore is more favorable than DBV Technologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DBV Technologies 2 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.43Immunocore 2 Sell rating(s) 4 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.33 SummaryImmunocore beats DBV Technologies on 12 of the 17 factors compared between the two stocks. Get DBV Technologies News Delivered to You Automatically Sign up to receive the latest news and ratings for DBVT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DBVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DBVT vs. The Competition Export to ExcelMetricDBV TechnologiesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$414.21M$3.44B$6.19B$10.60BDividend YieldN/A2.26%5.72%4.86%P/E Ratio-3.1223.2429.6428.46Price / Sales98.11477.59577.46128.87Price / CashN/A44.5736.5560.64Price / Book10.4610.3512.076.53Net Income-$113.92M-$52.53M$3.32B$276.75M7 Day Performance-12.59%-0.22%-0.16%0.20%1 Month Performance58.93%10.89%5.76%1.67%1 Year Performance336.99%14.19%65.71%32.73% DBV Technologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DBVTDBV Technologies1.3024 of 5 stars$14.86-1.7%$14.75-0.7%+332.0%$414.21M$4.15M-3.1280Positive NewsIMCRImmunocore2.6591 of 5 stars$32.35-0.2%$56.89+75.9%-2.4%$1.63B$310.20M-80.88320News CoverageAnalyst ForecastVCELVericel3.4108 of 5 stars$33.49+5.1%$60.40+80.4%-12.9%$1.61B$237.22M279.11300JANXJanux Therapeutics2.0635 of 5 stars$26.29-0.8%$78.31+197.9%-50.1%$1.59B$10.59M-14.6130News CoverageEWTXEdgewise Therapeutics3.2576 of 5 stars$14.71-2.6%$38.83+164.0%-56.7%$1.59BN/A-9.4960RCUSArcus Biosciences2.5953 of 5 stars$16.64+14.0%$26.78+61.0%-0.6%$1.55B$258M-5.25500Analyst ForecastHRMYHarmony Biosciences4.8023 of 5 stars$26.36-0.7%$46.11+74.9%-24.6%$1.53B$714.73M8.50200Positive NewsAUPHAurinia Pharmaceuticals2.7801 of 5 stars$11.10-1.5%$13.00+17.1%+67.2%$1.48B$235.13M25.81300Positive NewsPAHCPhibro Animal Health3.8448 of 5 stars$36.58+0.5%$28.40-22.4%+66.2%$1.48B$1.30B31.002,475Insider TradeSDGRSchrodinger3.5342 of 5 stars$19.70+3.2%$26.29+33.4%+11.3%$1.40B$207.54M-7.94790News CoverageHROWHarrow2.941 of 5 stars$38.77+3.4%$68.50+76.7%-31.7%$1.39B$199.61M-155.08180 Related Companies and Tools Related Companies Immunocore Alternatives Vericel Alternatives Janux Therapeutics Alternatives Edgewise Therapeutics Alternatives Arcus Biosciences Alternatives Harmony Biosciences Alternatives Aurinia Pharmaceuticals Alternatives Phibro Animal Health Alternatives Schrodinger Alternatives Harrow Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DBVT) was last updated on 10/23/2025 by MarketBeat.com Staff From Our PartnersRobinhood warningA strange chasm is coming to Wall Street... It's already creating millionaires and billionaires at the fast...Stansberry Research | Sponsored7 market signals flashing red right nowRight now, the same 7 key indicators that predicted 1929, the 1970s stagflation, and the 2008 meltdown are all...American Alternative | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DBV Technologies S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share DBV Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
